Collagenase clostridium histolyticum injections for Peyronie' s disease – our experience, outcomes and predictive factors for 100 patients
BAUS ePoster online library. Chiriaco G. Jun 24, 2019; 259532; P4-3
Giovanni Chiriaco
Giovanni Chiriaco
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
INTRODUCTION: to evaluate the efficacy, safety and predictive factors of collagenase clostridium histolyticum(CCH) in the treatment of Peyronie's disease(PD) using the modified treatment protocol.
METHODS:
a prospective study of 100 men with PD that completed at least 1 course(3 injections) of CCH treatment at a single centre. The majority(80%) received 1 course, with 15%(n=15) and 5%(n=5) completing 2 or 3 courses respectively. The angle of curvature assessment, International Index of Erectile Function (IIEF) and Peyronie's Disease Questionnaire (PDQ) were completed at baseline and 4 weeks after each course. Co-morbidities and risk factors for PD were recorded. The range of curvature improvement was assessed as improvement<14°;15°-20°;and >21°.
RESULTS:
The baseline curvature was 54±17°. There was mean improvement of 31%(17±10°) following 1 course . Following a second course there was a 36% improvement from baseline (23.3±10°). After a third course, 52.3%(35 ± 9°) improvement. There were significant improvements in IIEF and PDQ. CCH was well tolerated with one patient experiencing significant side effects (fracture). Overall 12%(n=12) patients experienced transient mild side effects. Following CCH treatment, 10%(10/100) opted for surgical correction. Men with a greater curvature(>70) and PD for greater than 12 months responded significantly better to CCH and were more satisfied.
CONCLUSIONS:
The modified protocol of CCH is a safe and effective non-surgical treatment option for PD. There is a sustained improvement from baseline penile curvature with second and third courses of treatment. Predictive factors include magnitude of curvature and having PD for more than 1 year.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings